At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 126 enrolled
Drug / intervention
Parsaclisibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
In Brief
A Phase 2 clinical trial evaluating Parsaclisib for Lymphoma. Completed, enrolled 126 participants across 83 sites in 13 countries.
Detailed Summary
The purpose of this study is to assess the objective response rate of parsaclisib treatment in participants with relapsed or refractory follicular lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesAustralia, Canada, Czechia, Denmark, Germany, Hungary, Israel, Italy, Poland, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartMar 2018
Primary CompletionFeb 2021
Study CompletionJun 2024
TodayJul 2026
First PostedApr 24, 2017
Enrollment StartMar 14, 2018
Primary CompletionFeb 26, 2021
Study CompletionJun 7, 2024
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 9.2 years ago
Interventions
Parsaclisibdrug
Parsaclisib tablets administered orally with water and without regard to food